NeuroSigma develops bioelectronic products to treat neurological and neuropsychiatric disorders, such as epilepsy, depression, ADHD, and PTSD. They are actively engaged in preclinical research and development, as well as clinical trials. Their lead product is a non-invasive trigeminal nerve stimulation (TNS) system for drug-resistant epilepsy and depressive disorder. They are also working on designing implantable TNS systems for patients who prefer an implantable option. NeuroSigma's technologies are based on intellectual property licensed from UCLA.